HNSCCs have a high rate of genetic heterogeneity3, resulting in loss-of-function mutations in tumour-suppressor genes such as p53 and p16INK4a, and activation of oncogenes, such as the epidermal growth factor receptor (EGFR)4 and PIK3CA5. Here, CDKN2A is linked to neoplasm.